Skip to content

To evaluate the safety & efficacy of Facial Oxylife Spot Reduction Bleach System

To evaluate the Safety & Efficacy of Facial Oxylife Spot Reduction Bleach System

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011928
Enrollment
35
Registered
2018-02-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Facial Oxylife Spot reduction Bleach System contains five products including : Pre-Bleach, Creme Bleach, Powder Activator, Active Serum, Post Bleach: 1. Pre-Bleach: It is composed of S

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female Adult Subjects in general good health with age group of 18 to 60 years. Subjects who have not undergone any bleaching or facial procedure in past 6 weeks. 2. Subjects willing to give a voluntary written informed consent for the participation in study and also photography release and agree to come for regular follow up. 3. Subjects willing to abide by and comply with the study protocol. 4. Subjects who are willing not to participate in any other clinical study during participation in the current study. 5. Subjects who will qualify the sensitivity test will be enrolled in the study.

Exclusion criteria

Exclusion criteria: 1. A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients, or any ingredient of the test product. 2. Present/current of intense sun exposure. 3. Female volunteers with positive pregnancy test. 4. Presence of any underlying clinically significant uncontrollable medical conditions 5. Subject having active skin diseases (e.g. mild, moderate to severe acne vulgaris on the face or nodulocystic acne, psoriasis, active atopic dermatitis, lichen planus pigmentosus/Ashy dermatosis, pigmented contact dermatitis and active seborrhoeic dermatitis, tinea faciei or other cutaneous manifestations), which may interfere with the test readings. 6. Subject on systematic medications (e.g. steroids, anti-oxidant) which may compromise the study. 7. Subjects who have excessive facial hair

Design outcomes

Primary

MeasureTime frame
1. Reduction in skin spots in comparison to baseline 2. Reduction in skin pigmentation in comparison to baseline. Timepoint: At Day 1, Day 3, Day 7 and Day 14

Secondary

MeasureTime frame
1. Assessment of bleaching system in improving glow and radiance. 2. Assessment of bleaching system in improving Detanning. 3. Assessment of bleaching system in improving skin clarity. 4. Assessment of bleaching system in improving skin colour. 5. To evaluate the safety and tolerability of bleaching system. Timepoint: At Day 1, Day 3, Day 7 and Day 14

Countries

India

Contacts

Public ContactRitambhara

Dabur India Limited

arun.gupta@dabur.com919910200255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026